# Eikonoklastes Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eikonoklastes-therapeutics

- Industry: Biotechnology
- Headquarters: Cincinnati, US
- Website: www.eikonoklastes.com
- Total disclosed funding: $3.2M
- Latest round: Series A (Apr 22, 2021)
- Investors on record: 3

## About

Eikonoklastes Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, focusing on enhancing neuromuscular signaling to improve patient outcomes.Founded in 2019 in Cincinnati, US, Eikonoklastes Therapeutics specializes in biopharmaceutical development, particularly in gene therapy. The company was co-founded by Bruce Halpryn and Samuel Lee, with Halpryn serving as CEO. Eikonoklastes has completed 3 deals and raised a total of USD 3.18 mn in a SERIES A funding round in April 2021, led by CincyTech and including investments from JobsOhio and Rev1 Ventures.Eikonoklastes Therapeutics™ develops biopharmaceutical solutions targeting neurodegenerative diseases. Their lead product, ET-101/SynCav1, is a novel gene therapy designed to enhance neuromuscular signaling by overexpressing Caveolin-1 in neurons, with applications in conditions such as ALS, Alzheimer’s, and Parkinson’s. The company partners with healthcare providers and research institutions in the US and select international markets, aiming to address critical patient needs.The revenue model of Eikonoklastes Therapeutics™ revolves around collaborations with healthcare institutions for clinical trial support and product development. Their business structure includes direct partnerships with medical centers, focusing on their gene therapy product ET-101. Revenue is generated through milestone payments, licensing fees, and revenue sharing from future sales, aligned with industry standards for biopharmaceutical therapies.Following a successful SERIES A funding of USD 3.18 mn on April 22, 2021, Eikonoklastes Therapeutics plans to utilize the funding to conduct investigational new drug enabling studies for their immune conjugate platform. The company aims to expand its product offerings and may target new markets in Western Europe and parts of Asia by 2023, seeking to enhance its therapeutic offerings in the neurodegenerative disease landscape.

## Funding rounds

- Series A, Apr 22, 2021, $3.2M — CincyTech, Rev1 Ventures, JobsOhio
- Seed, Jul 22, 2020 — CincyTech

## Investors

- CincyTech (https://capitalatlas.ai/funds/cincytech) — Seed, Series A
- Rev1 Ventures (https://capitalatlas.ai/funds/rev1-ventures) — Series A
- JobsOhio (https://capitalatlas.ai/funds/jobsohio) — Series A